The rise of Viagra initially fueled a surge for pharma, however recent shifts present a complicated picture for shareholders. Off-patent competitors are eroding revenue, and persistent legal battles add further https://karimznke697794.dailyblogzz.com/41666917/the-blue-pill-and-big-pharma-a-precarious-bet